These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 15610661)
1. Arsenic trioxide as a treatment for myelodysplastic syndrome. Sekeres MA Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661 [TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide as a treatment for myelodysplastic syndrome. Sekeres MA Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329 [TBL] [Abstract][Full Text] [Related]
3. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Welch JS; Klco JM; Gao F; Procknow E; Uy GL; Stockerl-Goldstein KE; Abboud CN; Westervelt P; DiPersio JF; Hassan A; Cashen AF; Vij R Am J Hematol; 2011 Sep; 86(9):796-800. PubMed ID: 21815182 [No Abstract] [Full Text] [Related]
4. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209 [TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Raza A; Buonamici S; Lisak L; Tahir S; Li D; Imran M; Chaudary NI; Pervaiz H; Gallegos JA; Alvi MI; Mumtaz M; Gezer S; Venugopal P; Reddy P; Galili N; Candoni A; Singer J; Nucifora G Leuk Res; 2004 Aug; 28(8):791-803. PubMed ID: 15203277 [TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646 [TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. Douer D; Tallman MS J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332 [TBL] [Abstract][Full Text] [Related]
8. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. List A; Beran M; DiPersio J; Slack J; Vey N; Rosenfeld CS; Greenberg P Leukemia; 2003 Aug; 17(8):1499-507. PubMed ID: 12886236 [TBL] [Abstract][Full Text] [Related]
9. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647 [TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. Tallman MS Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161 [No Abstract] [Full Text] [Related]
11. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Donelli A; Chiodino C; Panissidi T; Roncaglia R; Torelli G Haematologica; 2000 Sep; 85(9):1002-3. PubMed ID: 10980650 [No Abstract] [Full Text] [Related]
12. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204 [TBL] [Abstract][Full Text] [Related]
13. What is the role of arsenic in newly diagnosed APL? Tallman MS Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605 [TBL] [Abstract][Full Text] [Related]
14. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836 [TBL] [Abstract][Full Text] [Related]
15. Advances in management of acute promyelocytic leukemia with arsenic trioxide. Ma J Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904 [No Abstract] [Full Text] [Related]
16. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309 [TBL] [Abstract][Full Text] [Related]
18. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model]. Lu J; Jin J; Xu WL Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066 [TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. Galimberti S; Guerrini F; Salvi F; Petrini I; Gioia D; Messa E; Palumbo GA; Cilloni D; Petrini M; Levis A J Hematol Oncol; 2012 Sep; 5():53. PubMed ID: 22964015 [TBL] [Abstract][Full Text] [Related]